Frontiers in Pharmacology (Sep 2020)

Getting the Right Evidence After Drug Approval

  • Rick A. Vreman,
  • Rick A. Vreman,
  • Hubert G. M. Leufkens,
  • Aaron S. Kesselheim

DOI
https://doi.org/10.3389/fphar.2020.569535
Journal volume & issue
Vol. 11

Abstract

Read online

To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan.

Keywords